Recent news on Eptifibatide

Millennium Resumes Clinical Program For MLN0002  -  May 18, 2007
Medical News Today (press release),...the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

Millennium Reports Strong Financial and Operational Results for ...  -  26 Apr 2007
PharmaLive.com (press release),...the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

Millennium Discovers Biomarkers Potentially Predictive Of Response ...  -  Apr 18, 2007
Medical News Today (press release),...the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

The Moose in the Room  -  Apr 16, 2007
Scientist,But a head to head clinical trial comparing ReoPro to a competing antithrombotic, Integrilin (eptifibatide), published in 1998, suggested that the two drugs

Harnessing the therapeutic power of venom  -  Apr 12, 2007
BiopharmaReporter.com,Other drugs tied to venoms include Schering-Ploughs Integrilin (eptifibatide), to treat acute coronary syndrome. That drug is a platelet glycoprotein

Trial Looks at Timing of Anti-Clotting Drugs for Heart Attack Patients  -  Feb 13, 2007
Atlanta Journal Constitution (subscription),But glycoprotein IIb/IIIa inhibitors, which include abciximab or eptifibatide, can also help cut clotting risks. "All of the guidelines do recommend the use

The Timing Of Administration Of Platelet-Inhibiting Drugs  -  Feb 19, 2007
Medical News Today (press release),..."Furthermore, the upstream use of platelet glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors (tirofiban or eptifibatide) prior to angiography in patients with

Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in ...  -  Feb 13, 2007
Journal of American Medical Association (subscription),...of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome: study design and rationale.

Millennium Exceeds Non-GAAP Profitability Goal and Narrows GAAP ...  -  Feb 8, 2007
Earthtimes.org...the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

Effects of GP IIb/IIIa Inhibitors on Vascular Inflammation ...  -  Jan 17, 2007
HeartZine,Abciximab and the small-molecule GP IIb/IIIa inhibitors (eptifibatide, tirofiban) have separate, distinct binding sites on the GP IIb/IIIa receptor complex.

Millennium Achieves 2006 Non-GAAP Profitability, Reduces GAAP Net Loss  -  Jan 5, 2007
PharmaLive.com (press release),...the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

Dr. Bob Tepper, President of R&D, to Leave Millennium  -  Dec 14, 2006
Drug Newswire (press release),...the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

Dr. Bob Tepper, President of R&D, to Leave Millennium  -  Dec 14, 2006
Yahoo! News (press release)...government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving revenue consistent

Affimed´s Fully Human Anti Thrombosis Antibody Shows in Vivo ...  -  Dec 4, 2006
PharmaLive.com (press release),...that the antithrombotic effect is comparable to the clinically used conformation-unspecific GPIIb/GPIIIa blockers tirofiban and eptifibatide.

Millennium Initiates Phase II Trial to Evaluate MLN3897 in ...  -  Nov 28, 2006
Yahoo! News (press release)...the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

Initial Experience with the Use of Intravenous Eptifibatide Bolus ...  Oct 10, 2006
We assessed the safety of intravenous eptifibatide administered during aneurysm coiling procedures to prevent such complications. ... -AJNR (subscription), Millennium Achieves Non-GAAP Profitability and Reduces GAAP Net ...  Oct 26, 2006
...the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving ... -MSN Money GP IIb/IIIa inhibition: Time to drop the infusion?  Oct 11, 2006
...whereas in the GP IIb/IIIa arm, they gave the FDA-approved dose: they ran [abciximab or eptifibatide] for 12 to 24 hours, because that's what's in the package ... -TheHeart.Org, Millennium and Ortho Biotech Enter into US Co-Promotion Agreement ...  Oct 26, 2006
...the products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving revenue ... -Yahoo! News (press release) Millennium Issues Statement Regarding AnorMED Inc.  Oct 17, 2006
...and third-party reimbursement rates; the commercial success of VELCADE® (bortezomib) for Injection and INTEGRILIN® (eptifibatide) Injection; achieving ... -Yahoo! News (press release) Millennium Issues Statement Regarding AnorMed Inc.  Oct 17, 2006
...and third-party reimbursement rates; the commercial success of VELCADE(R) (bortezomib) for Injection and INTEGRILIN(R) (eptifibatide) Injection; achieving ... -PharmaLive.com (press release), Journal of Clinical Oncology Publishes Final Study Results of ...  Oct 9, 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving ... -Drug Newswire (press release), Roadmap To Integrin Activation Created By UCSD Researchers  Sep 21, 2006
Direct inhibitors of GPIIb-IIIa binding include antithrombotics such as eptifibatide (Integrelin), abciximab (Reopro), and tirofiban (Aggrestat), drugs that ... -Medical News Today

Millennium Announces Phase I Trial Of MLN0415 For Inflammatory ...  Aug 31, 2006
...the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving ... -Medical News Today

VELCADE(R) (bortezomib) for Injection Incorporated Into NCCN(R ...  -  12 Dec 2006
Drug Newswire (press release),...the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

Significant Data on VELCADE(R) (bortezomib) For Injection To Be ...  -  Dec 8, 2006
Yahoo! News (press release)...government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving revenue consistent

Affimed´s Fully Human Anti Thrombosis Antibody Shows in Vivo ...  -  Dec 4, 2006
PharmaLive.com (press release),...that the antithrombotic effect is comparable to the clinically used conformation-unspecific GPIIb/GPIIIa blockers tirofiban and eptifibatide.

FDA Grants Priority Review To VELCADE(R) (Bortezomib) For ...  Aug 11, 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving ... -Medical News Today

Millennium Reports Strong Financial Results and Significant ...  Jul 27, 2006
Royalties associated with INTEGRILIN® (eptifibatide) Injection worldwide sales and VELCADE ex-US sales were $34.2 million for the second quarter 2006. ... -Yahoo! News

Scientist who discovered nesiritide and eptifibatide dies  Jul 14, 2006
M Scarborough, the medicinal chemist who discovered two major cardiovascular drugs— nesiritide (Natrecor, Scios) and eptifibatide (Integrilin, Millennium ... -TheHeart.Org

PROTECT-TIMI-30 appears to favor bivalirudin over eptifibatide in ...  Jun 23, 2006
Boston, MA - The PROTECT-TIMI-30 study, comparing eptifibatide plus either unfractionated heparin or enoxaparin vs bivalirudin alone in ACS patients undergoing ... -TheHeart.Org

New Trials of Antithrombotic Therapy for ACS -- ACC 2006  Jul 21, 2006
...that randomized high-risk UA/NSTEMI patients to 1 of 3 arms: in 2 of the 3 arms patients received a GP IIb/IIIa inhibitor, either eptifibatide or tirofiban, in ... -Medscape (subscription)

USV set to bag AIIMS' typhoid vaccine tech  Jun 22, 2006
USV has already launched Eptifibatide, a platelet aggregation inhibitor, synthesised by its biotherapeutics division, into the domestic market. ... -Business Standard

VELCADE(R) (Bortezomib) For Injection Showed Unprecedented Results ...  Jun 22, 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving ... -Medical News Today



Similar Early Outcomes With Eptifibatide and Abciximab Before ...  16 May 2006
CHICAGO, IL -- May 15, 2006 -- The glycoprotein IIb/IIIa inhibitors abciximab and eptifibatide appear to be equally effective in improving in-hospital outcomes ... - DG News

Millennium Achieves First Quarter 2006 Non-GAAP Profitability and ...  Apr 27, 2006
...of lower net reimbursement received from Schering-Plough Corporation for sales, marketing and development activities for INTEGRILIN® (eptifibatide) Injection. ... - Yahoo! News

Millennium and Johnson & Johnson Pharmaceutical Research and ...  Apr 18, 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving ... - Yahoo! News





Clopidogrel Treatment Prior to Percutaneous Coronary Intervention  Apr 4, 2006
Abciximab, eptifibatide, and tirofiban were studied in several placebo-controlled trials involving nearly 17 000 patients undergoing nonemergent PCI. ... - Journal of American Medical Association (subscription)

Recommendations for Anticoagulated Patients Undergoing Image ...  Mar 21, 2006
This class of antiplatelet drugs includes abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat). Normal platelet ... - Am J Neuroradiology (subscription)

Drug-eluting and absorbable stents push interventional frontiers  Mar 13, 2006
448 medical centers in 17 countries performed a second comparison, randomly assigning 9,200 patients to receive either upfront GPI (eptifibatide or tirofiban ... - EurekAlert

The Medicines Company: hoping for a coronary coup  Mar 7, 2006
...addition of GPIIb/IIIa inhibitors such as Eli Lilly’s ReoPro (abciximab) and GlaxoSmithKline and Schering Plough’s Integrilin (eptifibatide) to heparin and ... - Pharmaceutical Business Review

Millennium Achieves $10 Million Milestone Payment  Mar 9, 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving ... - PharmaLive.com

Chairman of Cleveland Clinic Department of Cardiovascular Medicine ...  Feb 9, 2006
He was the first physician to administer recombinant t-PA, 2 different platelet glycoprotein IIb/IIIa inhibitors (abciximab and eptifibatide), and a new ... - International News Service,

Thrombolytic Treatment Before Stenting Linked to Increased ...  Feb 14, 2006
...no increase in mortality for patients pre-treated with glycoprotein IIb/IIIa inhibitors such as ReoPro (abciximab), Integrilin (eptifibatide), and Aggrastat ... - MedPage Today,

Millennium Announces New Senior Vice President of Human Resources  09 Feb 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving ... - PR Newswire

Accumetrics Raises $8.25 Million in Series C Financing  09 Feb 2006
In addition, there is a VerifyNow test for ReoPro(R) (abcimixmab) and Integrilin(R) (eptifibatide), both GP IIb/IIIa inhibitors, which are injectable ... - PR Newswire

Millennium Announces Appointments of Executive Vice President of ...  Jan 25, 2006
He joined Millennium in 2004 as the head of sales and marketing for INTEGRILIN® (eptifibatide) Injection, a product the Company sold the development and ... - Yahoo! News

Millennium Achieves 2005 Financial Guidance  Jan 26, 2006
...revenue of $123.5 million associated with the original collaboration agreement with Schering-Plough Corporation for INTEGRILIN(R) (eptifibatide) Injection. ... - Biotech Intelligence

Arginox Appoints Robert Terifay as President and Chief Operating ...  Jan 6, 2006
...of the company's commercial presence in the acute care cardiovascular market, taking the company's first product, INTEGRILIN(R) (eptifibatide) Injection to ... - PR Newswire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional